Skip to main content

Rheumatoid Arthritis

No Recurrent Cancer Risk With Biologic Treatment of RA

MedPage Today
Sep 24, 2021

Patients with rheumatoid arthritis (RA) who had a history of cancer did not have an increased risk of new or recurrent cancers if treated with biologic therapies, a meta-analysis found.

Read Article

RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)

Sep 23, 2021

Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID

Read Article
Insurance data (biologics only given to refractory pts) study of 249 (TKR) & 159 (THR) surgeries in ~6000 #RA pts. Pts on biologics had signif less TKR (aHR: 0.55) & THR (0.63) vs higher rates if on MTX, steroids, biologic switch or APL syndr https://t.co/4rwuYswqz7

Dr. John Cush @RheumNow( View Tweet )

Sep 22, 2021
Prospective study of 77 RA patients in remission --> vax w/ BNT162b2 (BioNTech-Pfizer) (w/ temp D/C of DMARDs per ACR) found a vaccine-related flare rate of 7/8% (6 pts) w/ 5/6 flares after 2nd dose (2.6 days), resolved w/in 2 wks https://t.co/YOL3YVS2ne

Dr. John Cush @RheumNow( View Tweet )

Sep 22, 2021
Regarding Pfizer 1133 tofacitinib Safety study and recent FDA JAKi warnings -- Dr. Roy Fleischmann has said, "“There is a small increase in risk,” “But is it clinically meaningful?”, Read full interview here https://t.co/2Wd5h69Dfq

Dr. John Cush @RheumNow( View Tweet )

Sep 21, 2021
Breakthrough infections from UK QResarch database: Among 6.95 million vaccinated, 74.1% recv two vaccine doses, there were 2031 covid-19 deaths & 1929 hosp admissions; ~4.0% deaths & admissions were >14 days after 2nd dose https://t.co/bbDsb1zLhX

Dr. John Cush @RheumNow( View Tweet )

Sep 20, 2021
Have you seen this download? How to define difficult RA--download now. https://t.co/6WGMEieHvK https://t.co/yYZdfyUQu0
Dr. John Cush @RheumNow( View Tweet )
Sep 20, 2021
Claims case-controlled study shows statin use does not increase the risk of #RA - 32,726 RA and matched controls ; statin use (34 vs 32%) slightly increased RA risk (OR 1.12, 1.06–1.18), but signif lost after correcting for hyperlipidemia https://t.co/EcTlyE1MPx

Dr. John Cush @RheumNow( View Tweet )

Sep 20, 2021
32 RA pts; each w/ 2 stool samples >6 mos apart - stool metagenome sequencing stool samples and pt activity assessed. Microbiome most influenced by age, followed by those achieving minimum clinically important improvement https://t.co/unaEOOuP34

Dr. John Cush @RheumNow( View Tweet )

Sep 17, 2021

RheumNow Podcast – Do More DMARDs Mean More Switching? (9.17.2021)

Sep 16, 2021

Smartphones and diet; COVID-19 and the numbers - reassuring or not, and what about masks?; and do more drugs mean more switching, less persistence, and patient adherence goes up...or down? All this and more news and journal reports in this week's episode.

Read Article
CARRA (Childhood Arthritis and Rheumatology Research Alliance) has compared 3 different treatment strategies for polyarticular JIA to identify the optimal time to biologic regimen. Read more… https://t.co/swXZ4FxB33 #RheumNow #medtwitter https://t.co/zqfd9IPeEf
Dr. John Cush @RheumNow( View Tweet )
Sep 16, 2021

Different Regimens but Equal Outcomes in Polyarticular JIA

Sep 15, 2021

CARRA (Childhood Arthritis and Rheumatology Research Alliance) has compared 3 different treatment strategies for polyarticular JIA to identify the optimal time to biologic regimen.



This prospective observational study used data from the STOP-JIA trial (Start Time Optimization of

Read Article

Pneumocystis Often Lethal in Dermatomyositis

MedPage Today
Sep 14, 2021

Patients with dermatomyositis who were positive for a myositis-specific antibody had a much higher incidence of and mortality associated with Pneumocystis jirovecii infection than patients with other antibody-negative idiopathic inflammatory myopathies, Chinese researchers found.

Read Article

High Drug Switching and Low Persistence in Rheumatoid Arthritis

Sep 13, 2021

Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians.



This retrospective analysis assessed treatment patterns among patients newly initiated on biologic

Read Article

ACR Comments on JAK Inhibitors and FDA Announcement

ACR
Sep 13, 2021

Following is a statement from ACR President David Karp, MD, PhD, on JAK inhibitors and FDA drug safety communication.

Read Article
Among patients with rheumatoid arthritis (RA), the strongest risk factors for the development of lymphoma were disease activity and severity, French researchers found. #RheumNow https://t.co/mEYtTl2WRs https://t.co/KTluamv9gj
Dr. John Cush @RheumNow( View Tweet )
Sep 09, 2021
Analysis of records from the Mass General Brigham healthcare system in the Boston area, shows that breakthrough infections (after receiving SARS-CoV-2 vaccines) in patients with SARDs are not uncommon, and may be severe or fatal. https://t.co/Ri5QipR7YY https://t.co/TaTFTKfAzm
Dr. John Cush @RheumNow( View Tweet )
Sep 09, 2021

Lymphoma in RA: Disease Activity Matters

MedPage Today
Sep 08, 2021

Among patients with rheumatoid arthritis (RA), the strongest risk factors for the development of lymphoma were disease activity and severity, French researchers found.

In a multivariate analysis, having a high Disease Activity Score in 28 joints (DAS28) at baseline conferred twice the risk for

Read Article
UK study shows PreClin RA, Establ #RA 1) have increased bowel permeability; 2) gut permeability worsens w/ activity; 3) gut-permeability markers not affected by treatment; 4) in a RA Mouse model-blocking gut permeability ameliorates arthritis https://t.co/HZNl56cQnn

Dr. John Cush @RheumNow( View Tweet )

Sep 08, 2021

COVID Breakthrough Infections in Rheumatic Patients

Sep 08, 2021

Analysis of records from the Mass General Brigham healthcare system in the Boston area, shows that breakthrough infections (after receiving SARS-CoV-2 vaccines) in patients with systemic autoimmune rheumatic diseases (SARDs) are not uncommon, and may be severe or fatal.



Researchers

Read Article
Dr. Cush is joined by rheumatology colleagues to discuss impressions and impact of the 9/1/21 FDA Drug Safety Communication to physicians regarding new label changes. #RheumNow https://t.co/F37SCpJnsW https://t.co/uhdOjFo0yP
Dr. John Cush @RheumNow( View Tweet )
Sep 08, 2021

ICYMI: The Greatest Rheumatologist - Part II

Sep 06, 2021

Wow! I hope you read part I of yesterday's “Greatest Rheumatologist” article.  So many big names and yet, other names and stories that were equally inspirational.



If you read the comments of the part I article you can clearly see several themes emerge.

Read Article

ICYMI: The Greatest Rheumatologist - Part I

Sep 06, 2021

Who is the greatest rheumatologist? What makes for a great rheum? Is it clinical acumen, scientific achievement, educational prowess or years of unrivaled service or mentoring? Rheumatologists are quite opinionated on this subject and very nostalgic about their mentors and leaders. When I’ve

Read Article
FDA JAKi Warnings, 2nd Panel of rheumatologists weigh in on this. Drs. Cush, Dao, Tate, Sparks, Shergy. https://t.co/eETzP8DspC via @YouTube #RheumNow @KDAO2011 @uptoTate @jeffsparks @WilliamShergy https://t.co/iqxFQjJQ0l
Dr. John Cush @RheumNow( View Tweet )
Sep 06, 2021

Expert Panel: Initial Views on FDA Warnings for JAK Inhibitors

Sep 02, 2021

Dr. Jack Cush is joined by Drs. Roy Fleischmann (Dallas), Allan Gibofsky (NYC), and Artie Kavanaugh (San Diego) to discuss the 9/2/21 FDA Drug Safety Communication regarding the cardiovascular and cancer risks arising from the Pfizer 1133 (ORAL Surveillance) tofacitinib study, but also applied

Read Article
×